Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab + XELOX in First-Line Gastro-esophageal Cancer
NCT03342937Phase 2Completed
- Sponsor
- Duke University
- Start
- Jan 2018
- Primary completion
- Feb 2023
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in esophageal adenocarcinoma (EAC), gastric adenocarcinoma, sponsored by Duke University. Started Jan 2018; status: completed.
02
Drugs
03
Conditions
esophageal adenocarcinoma (EAC)gastric adenocarcinoma
Beyond the preview
Go deeper on NCT03342937.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03342937.